These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 26578208)

  • 1. Improved therapeutic activity of HER2 Affibody-targeted cisplatin liposomes in HER2-expressing breast tumor models.
    Alavizadeh SH; Akhtari J; Badiee A; Golmohammadzadeh S; Jaafari MR
    Expert Opin Drug Deliv; 2016; 13(3):325-36. PubMed ID: 26578208
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting, bio distributive and tumor growth inhibiting characterization of anti-HER2 affibody coupling to liposomal doxorubicin using BALB/c mice bearing TUBO tumors.
    Akhtari J; Rezayat SM; Teymouri M; Alavizadeh SH; Gheybi F; Badiee A; Jaafari MR
    Int J Pharm; 2016 May; 505(1-2):89-95. PubMed ID: 27039149
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hyperthermia-triggered intracellular delivery of anticancer agent to HER2(+) cells by HER2-specific affibody (ZHER2-GS-Cys)-conjugated thermosensitive liposomes (HER2(+) affisomes).
    Smith B; Lyakhov I; Loomis K; Needle D; Baxa U; Yavlovich A; Capala J; Blumenthal R; Puri A
    J Control Release; 2011 Jul; 153(2):187-94. PubMed ID: 21501640
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HER2-specific affibody-conjugated thermosensitive liposomes (Affisomes) for improved delivery of anticancer agents.
    Puri A; Kramer-Marek G; Campbell-Massa R; Yavlovich A; Tele SC; Lee SB; Clogston JD; Patri AK; Blumenthal R; Capala J
    J Liposome Res; 2008; 18(4):293-307. PubMed ID: 18937120
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Conjugated nanoliposome with the HER2/neu-derived peptide GP2 as an effective vaccine against breast cancer in mice xenograft model.
    Razazan A; Behravan J; Arab A; Barati N; Arabi L; Gholizadeh Z; Hatamipour M; Reza Nikpoor A; Momtazi-Borojeni AA; Mosaffa F; Ghahremani MH; Jaafari MR
    PLoS One; 2017; 12(10):e0185099. PubMed ID: 29045460
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sterically stabilized anti-HER2 immunoliposomes: design and targeting to human breast cancer cells in vitro.
    Kirpotin D; Park JW; Hong K; Zalipsky S; Li WL; Carter P; Benz CC; Papahadjopoulos D
    Biochemistry; 1997 Jan; 36(1):66-75. PubMed ID: 8993319
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting of epidermal growth factor receptor (EGFR)-expressing tumor cells with sterically stabilized affibody liposomes (SAL).
    Beuttler J; Rothdiener M; Müller D; Frejd FY; Kontermann RE
    Bioconjug Chem; 2009 Jun; 20(6):1201-8. PubMed ID: 19435362
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Encapsulation, controlled release, and antitumor efficacy of cisplatin delivered in liposomes composed of sterol-modified phospholipids.
    Kieler-Ferguson HM; Chan D; Sockolosky J; Finney L; Maxey E; Vogt S; Szoka FC
    Eur J Pharm Sci; 2017 May; 103():85-93. PubMed ID: 28263913
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The influence of phospholipid on the physicochemical properties and anti-tumor efficacy of liposomes encapsulating cisplatin in mice bearing C26 colon carcinoma.
    Alavizadeh SH; Badiee A; Golmohammadzadeh S; Jaafari MR
    Int J Pharm; 2014 Oct; 473(1-2):326-33. PubMed ID: 25051111
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of synthetic peptide-modified liposomes with LDL receptor targeting capacity and improved anticancer activity.
    Liu M; Li W; Larregieu CA; Cheng M; Yan B; Chu T; Li H; Mao SJ
    Mol Pharm; 2014 Jul; 11(7):2305-12. PubMed ID: 24830852
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improved drug delivery and therapeutic efficacy of PEgylated liposomal doxorubicin by targeting anti-HER2 peptide in murine breast tumor model.
    Zahmatkeshan M; Gheybi F; Rezayat SM; Jaafari MR
    Eur J Pharm Sci; 2016 Apr; 86():125-35. PubMed ID: 26972276
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic Efficacy of Cisplatin Thermosensitive Liposomes upon Mild Hyperthermia in C26 Tumor Bearing BALB/c Mice.
    Alavizadeh SH; Gheybi F; Nikpoor AR; Badiee A; Golmohammadzadeh S; Jaafari MR
    Mol Pharm; 2017 Mar; 14(3):712-721. PubMed ID: 28135098
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimizing the therapeutic efficacy of cisplatin PEGylated liposomes via incorporation of different DPPG ratios: In vitro and in vivo studies.
    Marzban E; Alavizadeh SH; Ghiadi M; Khoshangosht M; Khashayarmanesh Z; Abbasi A; Jaafari MR
    Colloids Surf B Biointerfaces; 2015 Dec; 136():885-91. PubMed ID: 26547316
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting of pegylated liposomal mitomycin-C prodrug to the folate receptor of cancer cells: Intracellular activation and enhanced cytotoxicity.
    Patil Y; Amitay Y; Ohana P; Shmeeda H; Gabizon A
    J Control Release; 2016 Mar; 225():87-95. PubMed ID: 26809007
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Affibody-displaying bionanocapsules for specific drug delivery to HER2-expressing cancer cells.
    Shishido T; Mieda H; Hwang SY; Nishimura Y; Tanaka T; Ogino C; Fukuda H; Kondo A
    Bioorg Med Chem Lett; 2010 Oct; 20(19):5726-31. PubMed ID: 20801029
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of maleimide derivative of DOTA for site-specific labeling of recombinant affibody molecules.
    Ahlgren S; Orlova A; Rosik D; Sandström M; Sjöberg A; Baastrup B; Widmark O; Fant G; Feldwisch J; Tolmachev V
    Bioconjug Chem; 2008 Jan; 19(1):235-43. PubMed ID: 18163536
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Her2-targeted pegylated liposomal doxorubicin: retention of target-specific binding and cytotoxicity after in vivo passage.
    Shmeeda H; Tzemach D; Mak L; Gabizon A
    J Control Release; 2009 Jun; 136(2):155-60. PubMed ID: 19331844
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor-targeted PE38KDEL delivery via PEGylated anti-HER2 immunoliposomes.
    Gao J; Zhong W; He J; Li H; Zhang H; Zhou G; Li B; Lu Y; Zou H; Kou G; Zhang D; Wang H; Guo Y; Zhong Y
    Int J Pharm; 2009 Jun; 374(1-2):145-52. PubMed ID: 19446771
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Poly(ethylene glycol)-block-poly(ε-caprolactone)-and phospholipid-based stealth nanoparticles with enhanced therapeutic efficacy on murine breast cancer by improved intracellular drug delivery.
    He X; Li L; Su H; Zhou D; Song H; Wang L; Jiang X
    Int J Nanomedicine; 2015; 10():1791-804. PubMed ID: 25784805
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rapamycin-loaded Immunoliposomes Functionalized with Trastuzumab: A Strategy to Enhance Cytotoxicity to HER2-positive Breast Cancer Cells.
    Eloy JO; Petrilli R; Brueggemeier RW; Marchetti JM; Lee RJ
    Anticancer Agents Med Chem; 2017; 17(1):48-56. PubMed ID: 27225450
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.